pharmaphorum
FEBRUARY 3, 2022
Legislation is already in place allowing companies to grow the plant for medicinal purposes under license, doctors have been able to prescribe it since 2017 with full reimbursement from health insurers.
The Pharma Data
DECEMBER 20, 2020
Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JULY 6, 2022
The regulator has revised the emergency use authorisation (EUA) for Paxlovid (nirmatrelvir and ritonavir) to allow state-licensed pharmacists to prescribe the drug to patients, providing they can provide recent health records and a list of current medicines they are taking. — President Biden (@POTUS) July 7, 2022. It made $1.5
Druggist
DECEMBER 28, 2020
The Government recently announced the reclassification of fexofenadine 120mg, which will be available as General sale Medication (GSL), sold as branded products – Allevia 120mg tablets. When to speak to a pharmacist or a doctor before taking Allevia tablets? Until now, fexofenadine was a prescription-only medication.
Pharmacy Checkers
DECEMBER 10, 2020
In 2017, a group of activists, policy professionals, lawyers, and doctors came together in Brussels at the RightsCon conference to draft the Brussels Principles on the Sale of Medicines Over the Internet. FDA because its label is not the one required for the sale of that drug in the U.S. It’s the exact same drug sold here.
pharmaphorum
JUNE 6, 2022
Approval in that broader patient range could unlock $3 billion in additional sales for Enhertu, according to analysts at Credit Suisse. billion upfront to license rights to Enhertu in a deal that could be worth up to $6.9 billion to Daiichi Sankyo if all the ADC’s development and sales objectives are achieved. AZ paid $1.4
Pharmaceutical Technology
JANUARY 6, 2023
This class-action litigation specifically focused on a 2011 licensing agreement between the two companies. In a press release, the company said a generic launch would damage sales in FY 2023 by $300,000. In September, Novartis announced its plans to petition the US Supreme Court to reverse the aforementioned decision.
Expert insights. Personalized for you.
109 
Let's personalize your content